Group 1: Telomir Pharmaceuticals Inc - Telomir Pharmaceuticals Inc's shares rose 31% to $1.86 in pre-market trading following the release of promising preclinical study results for its lead compound, Telomir-1 [1] - The preclinical study indicated that Telomir-1 was able to reverse abnormal DNA methylation in aggressive prostate cancer models [1] Group 2: Other Stocks in Pre-Market Trading - Spruce Biosciences Inc gained 90.9% to $248.89, while C3is Inc surged 73.3% to $3.83 in pre-market trading [5] - Aptevo Therapeutics Inc increased by 40.2% to $1.98, and Galecto Inc rose 37.5% to $5.10 [5] - Datavault AI Inc surged 27.8% to $2.66, reaffirming its 2H 2025 revenue guidance of $12 million to $15 million [5] - Processa Pharmaceuticals Inc gained 27.5% to $0.36, and BTQ Technologies Corp rose 25.7% to $11.44 [5] - DBV Technologies SA gained 12.8% to $14.99 after announcing the sale of approximately $30 million of ADSs [5] - Amkor Technology Inc jumped 11.2% to $33.99, announcing an expanded investment in semiconductor packaging and testing in Arizona [5] Group 3: Declining Stocks - Society Pass Inc shares dipped 24.6% to $4.00 after a significant jump of 276% on Monday [5] - Dermata Therapeutics Inc fell 19.1% to $4.35, and Aether Holdings Inc declined 16.8% to $4.51 [5] - SANUWAVE Health Inc dipped 14.4% to $34.99, cutting its FY25 revenue guidance from $48 million-$50 million to $44 million-$46 million [5] - Lazydays Holdings Inc fell 12.3% to $2.57, while NOVONIX Ltd tumbled 12.3% to $1.57 [5] - OneMedNet Corp dipped 12.1% to $2.25 after a significant jump of 149% on Monday [5]

Earnings Expectations - Wall Street anticipates McCormick & Company Inc. to report quarterly earnings of 81 cents per share with revenue projected at $1.71 billion [2] - Analysts expect Penguin Solutions Inc. to post quarterly earnings of 38 cents per share on revenue of $342.11 million [2] - Saratoga Investment Corp. is expected to report quarterly earnings of 68 cents per share with revenue of $31.98 million [2] Stock Performance - McCormick shares increased by 1.3% to $69.19 in after-hours trading [2] - SANUWAVE Health Inc. shares fell by 19.2% to $33.00 after issuing preliminary third-quarter revenue results below estimates and cutting FY25 revenue guidance from $48 million-$50 million to $44 million-$46 million [2] - Penguin Solutions shares rose by 1.7% to $29.80 in after-hours trading [2] - Telomir Pharmaceuticals Inc. shares surged by 38.7% to $1.97 following promising preclinical study results for its lead compound, Telomir-1 [2]

Group 1: Telomir Pharmaceuticals Inc. (TELO) - Shares surged 43% in after-hours trading, climbing from $1.42 to $2.03 on light volume of 213,569 shares, below the average daily volume of 4.67 million [2] - The spike reflects renewed interest in recent in vitro data showing Telomir-1's ability to target additional histone demethylase families, indicating a unique epigenetic profile [3] Group 2: Processa Pharmaceuticals Inc. (PCSA) - Shares rose 32.6% in after-hours trading to $0.37, following a 30.9% gain during the regular session, with a closing price of $0.2790 on volume exceeding 31.9 million shares [4] - The price movement occurred without any official news or updates from the company, suggesting speculative momentum or technical positioning [5] Group 3: Reviva Pharmaceuticals Holdings Inc. (RVPH) - Shares increased 33.7% in after-hours trading to $0.8950 after a regular session gain of 22.8%, closing at $0.6693 with significant trading volume of 34.2 million shares [6] - The rally happened despite no recent official news, with the last update being four days prior regarding a healthcare conference [7] Group 4: NeuroOne Medical Technologies Corp. (NMTC) - Shares rose 9.5% in after-hours trading to $1.09, extending a 7.1% gain during the regular session, with a closing price of $0.9956 and trading volume of 1.21 million shares [8] - The increase followed the announcement of preliminary unaudited product revenue of $9.1 million for fiscal year 2025, up 163% from the prior year, and an upcoming virtual webinar [9] Group 5: BioRestorative Therapies Inc. (BRTX) - Shares edged 4.6% higher in after-hours trading to $1.60, following a modest 2% gain during the regular session, with a closing price of $1.53 and trading volume of 415,798 shares [10] - The increase followed the announcement of a $1.085 million registered direct offering priced at $1.60 per share, with proceeds aimed at advancing clinical trials and other corporate purposes [11]

Core Viewpoint - Telomir Pharmaceuticals Inc. experienced a significant stock price increase of 38.71% in after-hours trading following the announcement of promising preclinical study results for its lead compound, Telomir-1, which is aimed at reversing DNA methylation in aggressive prostate cancer models [1][2]. Group 1: Study Results - Telomir-1 was reported to reverse abnormal DNA methylation, restoring the function of key tumor suppressor genes MASPIN and RASSF1A, which are often silenced in cancer due to hypermethylation [2][3]. - MASPIN is critical for blocking tumor invasion, regulating cell migration, promoting apoptosis, and enhancing treatment sensitivity. Telomir-1 effectively restored MASPIN activity in vivo by reversing chemotherapy-induced DNA methylation [4]. - RASSF1A is involved in cell cycle control, promoting apoptosis, and suppressing metastasis. Telomir-1 reduced RASSF1A methylation in a dose-dependent manner, with enhanced effects when combined with chemotherapy [5]. Group 2: Development Status - The company is continuing preclinical development with IND-enabling studies for Telomir-1 [6]. Group 3: Stock Performance - Year-to-date, TELO stock is down 65.53%, but has gained 15.45% over the past month. The stock has traded between $1.12 and $7.08 over the past year, with a market capitalization of $45.84 million and an average daily trading volume of 3.33 million shares [7].

Core Insights - Telomir Pharmaceuticals, Inc. has announced new in vitro results indicating that Telomir-1 adds KDM5 family inhibition to its previously reported KDM2/KDM6 and DNA methylation activity, suggesting a potential advancement in epigenetic therapy [1] Company Summary - Telomir Pharmaceuticals, Inc. is a preclinical-stage biotechnology company focused on developing therapies that target the root causes of cancer, aging, and age-related diseases [1] - The company is listed on NASDAQ under the ticker TELO [1] Industry Summary - The results from Telomir-1 may represent a novel frontier in epigenetic therapy, an area where no existing candidates have demonstrated comparable breadth [1] - The inhibition of three members of the KDM5 histone demethylase family by Telomir-1 highlights the potential for innovative therapeutic approaches in the field of epigenetics [1]

Financial Performance - For the three months ended June 30, 2025, the company reported a net loss of $5.1 million, compared to a net loss of $1.4 million for the same period in 2024, representing a significant increase in losses [78]. - The company incurred a total net loss of $7.2 million for the six months ended June 30, 2025, compared to a net loss of $7.7 million for the same period in 2024 [78]. - The company reported negative cash flow from operations of approximately $1.6 million for the six months ended June 30, 2025, compared to $3.5 million for the same period in 2024 [101]. Expenses - Research and development expenses for the three months ended June 30, 2025, were $0.04 million, a decrease from $0.6 million in the same period of 2024, primarily due to a credit received in 2024 [89]. - General and administrative expenses increased to $5.0 million for the three months ended June 30, 2025, from $0.9 million in 2024, largely due to a $4.6 million increase in stock compensation expenses [94]. - The company expects research and development expenses to increase as it advances Telomir-1 into clinical trials and pursues regulatory approvals [93]. Cash Position - As of June 30, 2025, the company had cash and cash equivalents of approximately $0.8 million and an accumulated deficit of approximately $37.8 million [101]. - The company has entered into an unsecured Promissory Note with the Starwood Trust, allowing it to borrow up to $5 million, with no amounts borrowed as of June 30, 2025 [99]. Funding - The company raised $3 million in equity financing through a direct investment by The Bayshore Trust, issuing 333,333 restricted shares at $3.00 per share, an 18% premium to the closing share price on the execution date [100]. Revenue Generation - The company has not generated any revenue since inception and does not anticipate doing so until successful completion of preclinical and clinical development [91].

Company Performance - 3M Company reported second-quarter 2025 results with GAAP sales of $6.3 billion, reflecting a year-over-year increase of 1.4% and adjusted sales of $6.2 billion, which beat the consensus estimate of $6.09 billion [2] - Adjusted earnings per share rose 12% year over year to $2.16, surpassing the Street estimate of $2.01 [2] Future Guidance - 3M raised its 2025 Adjusted EPS guidance to a range of $7.75-$8.00 from a prior range of $7.60-$7.90, compared to the consensus of $7.68 [3] - The company expects 2025 adjusted sales organic growth of approximately 2%, with operating cash flow projected between $5.1 billion and $5.5 billion, indicating over 100% free cash flow conversion [3] Stock Movements - Telomir Pharmaceuticals, Inc. saw its shares increase by 81% to $2.19 following the announcement of gene silencing data [8] - MEI Pharma, Inc. shares surged 33% to $5.99 after announcing a $100 million private placement [8] - Blaize Holdings, Inc. shares rose 45% to $4.39 after a $120 million agreement for deploying its hybrid AI platform [8] - LQR House Inc. shares dropped 65% to $2.29 due to plans to integrate cryptocurrency and blockchain technology [8] - Northern Dynasty Minerals Ltd. shares fell 48% to $0.8398 after insider trading disclosures [8] - Draganfly Inc. shares decreased by 23% to $5.55 following a $25 million registered direct offering [8]

Part I. Financial Information This section covers the company's unaudited condensed financial statements and management's discussion and analysis [Item 1. Condensed Financial Statements (unaudited)](index=3&type=section&id=Item%201.%20Condensed%20Financial%20Statements%20(unaudited)) Unaudited condensed financial statements for Telomir Pharmaceuticals, Inc. are presented for Q1 2025 and year-end 2024 - The company is classified as a non-accelerated filer and a smaller reporting company[4](index=4&type=chunk) - As of May 14, 2025, there were **29,762,671** shares of registrant common stock issued and outstanding[5](index=5&type=chunk) [Condensed Balance Sheets](index=4&type=section&id=Condensed%20Balance%20Sheets) This section presents the company's financial position as of March 31, 2025, and December 31, 2024 Condensed Balance Sheets (Unaudited) | Metric | March 31, 2025 | December 31, 2024 | | :-------------------------------- | :------------- | :---------------- | | Cash and cash equivalents | $402,999 | $1,266,131 | | Total current assets | $491,188 | $1,324,005 | | Total assets | $491,188 | $1,324,005 | | Total current liabilities | $652,294 | $680,968 | | Total liabilities | $652,294 | $680,968 | | Total stockholders' equity (deficit) | $(161,106) | $643,037 | [Condensed Statements of Operations](index=5&type=section&id=Condensed%20Statements%20of%20Operations) This section presents the company's financial performance, including revenues and net loss, for Q1 2025 and Q1 2024 Condensed Statements of Operations (Unaudited) | Metric | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :-------------------------------- | :-------------------------------- | :-------------------------------- | | Revenues | $0 | $0 | | General and administrative expenses | $1,850,786 | $741,541 | | Related party travel costs | $0 | $370,500 | | Research and development expenses | $336,996 | $804,023 | | Total operating costs | $2,187,782 | $1,916,064 | | Interest income (expense), net | $7,954 | $(4,338,543) | | Net loss | $(2,179,828) | $(6,254,607) | | Basic and diluted loss per share | $(0.07) | $(0.23) | | Weighted average common stock shares outstanding | 29,762,671 | 29,276,481 | [Condensed Statements of Changes in Stockholders' Equity (Deficit)](index=6&type=section&id=Condensed%20Statements%20of%20Changes%20in%20Stockholders'%20Equity%20(Deficit)) This section outlines changes in the company's stockholders' equity (deficit) for Q1 2025 and Q1 2024 Condensed Statements of Changes in Stockholders' Equity (Deficit) - Three Months Ended March 31, 2025 (Unaudited) | Item | Three Months Ended March 31, 2025 | | :-------------------------- | :-------------------------------- | | Balances, December 31, 2024 | $643,037 | | Stock based compensation | $1,375,686 | | Net loss | $(2,179,828) | | Balances, March 31, 2025 | $(161,106) | Condensed Statements of Changes in Stockholders' Equity (Deficit) - Three Months Ended March 31, 2024 (Unaudited) | Item | Three Months Ended March 31, 2024 | | :-------------------------------- | :-------------------------------- | | Balances, December 31, 2023 | $3,438,204 | | Issuance of common stock for cash, net | $5,832,973 | | Net loss | $(6,254,607) | | Balances, March 31, 2024 | $3,016,570 | [Condensed Statements of Cash Flows](index=7&type=section&id=Condensed%20Statements%20of%20Cash%20Flows) This section presents the company's cash flows from operating and financing activities for Q1 2025 and Q1 2024 Condensed Statements of Cash Flows (Unaudited) | Activity | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :-------------------------- | :-------------------------------- | :-------------------------------- | | Net cash from operating activities | $(863,132) | $(1,939,415) | | Net cash from financing activities | $0 | $5,212,498 | | Net change in cash and cash equivalents | $(863,132) | $3,273,083 | | Cash and cash equivalents, end of period | $402,999 | $3,274,314 | [Notes to Condensed Financial Statements (unaudited)](index=8&type=section&id=Notes%20to%20Condensed%20Financial%20Statements%20(unaudited)) This section provides explanatory notes to the unaudited condensed financial statements - The accompanying unaudited condensed financial statements are prepared in accordance with GAAP for interim financial information and Regulation S-X[17](index=17&type=chunk) [Note 1. Description of business and summary of significant accounting policies](index=8&type=section&id=Note%201.%20Description%20of%20business%20and%20summary%20of%20significant%20accounting%20policies) This note describes the company's business, Telomir-1, and significant accounting policies - Telomir-1 is a novel oral small molecule metal ion regulator designed to extend telomere caps, maintain cellular balance, and combat oxidative stress, a key driver of aging and disease progression[16](index=16&type=chunk) - Telomir-1 may help protect against age-related conditions (Progeria, Wilson's disease, Age-related Macular Degeneration, Type 2 Diabetes, cancer, Alzheimer's disease) and mitigate viral infection severity[16](index=16&type=chunk) - Research and development costs are expensed in the period in which they are incurred[18](index=18&type=chunk) - As of March 31, 2025, the Company had approximately **$0.2 million** in cash in excess of FDIC limits[21](index=21&type=chunk) - The Company does not expect the adoption of new accounting guidance (ASU 2024-03 and ASU 2023-09) to have a material impact on its consolidated financial statements[29](index=29&type=chunk)[31](index=31&type=chunk) [Note 2. Going concern](index=11&type=section&id=Note%202.%20Going%20concern) This note discusses the company's financial condition and its ability to continue as a going concern - As of March 31, 2025, the Company had cash of approximately **$0.4 million**, used approximately **$0.9 million** in operations, and reported a net loss of **$2.2 million** for the three months ended March 31, 2025[34](index=34&type=chunk) - The Company had a stockholders' deficit and working capital deficit of approximately **$0.2 million** as of March 31, 2025, compared to stockholders' equity of approximately **$0.6 million** at December 31, 2024[34](index=34&type=chunk) - These factors raise substantial doubt about the Company's ability to continue as a going concern for at least the next 12 months, necessitating significant additional external funding[35](index=35&type=chunk)[36](index=36&type=chunk) [Note 3. License agreement, related party](index=11&type=section&id=Note%203.%20License%20agreement,%20related%20party) This note details the company's exclusive license agreement for Telomir-1 with related party MIRALOGX, LLC - The Company licenses U.S. patent rights for Telomir-1 from MIRALOGX, LLC, an entity established by the Company's founder and sole inventor of Telomir-1[37](index=37&type=chunk) - The exclusive perpetual license covers human and animal therapeutic uses, with an **8% royalty** on net sales and non-royalty bearing milestone revenue, though no payments have been made to date[39](index=39&type=chunk)[40](index=40&type=chunk) - The patent rights are expected to extend through 2043, with potential for additional patent terms[41](index=41&type=chunk) [Note 4. Related party transactions](index=12&type=section&id=Note%204.%20Related%20party%20transactions) This note describes various transactions and agreements between the company and related parties - An amount of **$0.1 million** in working capital advances from companies under common control remains outstanding as of March 31, 2025[43](index=43&type=chunk) - The Company has an unsecured Promissory Note and Loan Agreement with the Starwood Trust (a related party) for up to **$5 million** at **7% interest**, due on September 24, 2026; no amounts have been borrowed as of March 31, 2025[44](index=44&type=chunk) - On December 9, 2024, Starwood Trust purchased **142,857 shares** of unregistered common stock for **$1.0 million**[46](index=46&type=chunk) [Note 5. Stockholders' equity (deficit)](index